Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.

Summary Expression Phenotypes Gene Literature (109) GO Terms (8) Nucleotides (96) Proteins (50) Interactants (371) Wiki
XB-GENEPAGE-1000155

Papers associated with gcg



???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? ???pagination.result.prev??? 1 2 3

Sort Newest To Oldest Sort Oldest To Newest

Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents., Han J, Fu J, Yang Q, Zhou F, Chen X, Li C, Yin J., Eur J Med Chem. July 15, 2020; 198 112389.

Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes., Chen X, Fu J, Zhou F, Yang Q, Wang J, Feng H, Jiang W, Jin L, Tang X, Jiang N, Yin J, Han J., J Med Chem. November 12, 2020; 63 (21): 12595-12613.

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists., Jiang N, Jing L, Li Q, Su S, Yang Q, Zhou F, Chen X, Han J, Tang C, Tang W., Eur J Med Chem. February 15, 2021; 212 113118.

Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease., Han C, Sun Y, Yang Q, Zhou F, Chen X, Wu L, Sun L, Han J., Mol Pharm. August 2, 2021; 18 (8): 2906-2923.

Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents., Yang Q, Zhou F, Tang X, Wang J, Feng H, Jiang W, Jin L, Jiang N, Yuan Y, Han J, Yan Z., Eur J Med Chem. April 5, 2022; 233 114214.

Nutritional control of thyroid morphogenesis through gastrointestinal hormones., Takagishi M, Aleogho BM, Okumura M, Ushida K, Yamada Y, Seino Y, Fujimura S, Nakashima K, Shindo A., Curr Biol. April 11, 2022; 32 (7): 1485-1496.e4.                            

A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes., Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, Sun L, Yang Q, Tang X, Yuan Y, Han J, Jiang N., Br J Pharmacol. September 1, 2022; 179 (17): 4360-4377.

Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity., Li Q, Yang Q, Han J, Liu X, Fu J, Yin J., Chin J Nat Med. November 1, 2022; 20 (11): 863-872.

Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist., Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, Han J, Zhao S., Eur J Med Chem. February 5, 2023; 247 115036.

???pagination.result.page??? ???pagination.result.prev??? 1 2 3